Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 9/20 | 0.31 |
| ▸ | FNTB | P49356 | 7/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3690678 | 1.00 | BTN3A1 (0.37) | BTN3A1FDPSBLMTDP1FNTA | |
| SCHEMBL156446 | 0.98 | BTN3A1 (0.38) | BTN3A1FDPSBLMTDP1FNTA | |
| Pyrophosphoric Acid SCHEMBL3890468 | 0.96 | FDPS (0.42) | BTN3A1FDPSBLMTDP1FNTA | |
| SCHEMBL18486678 | 0.94 | BTN3A1 (0.36) | BTN3A1FDPSBLMTDP1FNTA | |
| SCHEMBL9901912 | 0.89 | LMNA (0.31) | — | |
| SCHEMBL16930867 | 0.89 | BTN3A1 (0.40) | BTN3A1FDPSBLMTDP1FNTA | |
| Pyrophosphoric Acid SCHEMBL16011213 | 0.87 | BTN3A1 (0.39) | BTN3A1FDPSBLMTDP1FNTA | |
| SCHEMBL11336328 | 0.84 | LMNA (0.33) | FDPS | |
| SCHEMBL21571326 | 0.83 | BTN3A1 (0.47) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL1004249 | 0.80 | SMPD1 (0.33) | FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| CN-115175758-A | Thermally expandable microspheres, process for producing the same, and use thereof | 松本油脂制药株式会社 | 2022-10-11 | — | — | CN | disclosed |
| US-20190054186-A1 | Magnetic Nanoparticle-Polymer Complexes and uses Thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2019-02-21 | — | — | US | disclosed |
| US-10184137-B2 | Method of producing isoprene monomer | AJINOMOTO CO., INC. (JP) | 2019-01-22 | — | — | US | disclosed |
| WO-2017173205-A1 | MAGNETIC NANOPARTICLE-POLYMER COMPLEXES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-3122868-A2 | METHOD OF PRODUCING ISOPRENE MONOMER | Ajinomoto Co., Inc. (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20150275233-A1 | METHOD OF PRODUCING ISOPRENE MONOMER | AJINOMOTO CO., INC. (JP) | 2015-10-01 | — | — | US | disclosed |
| US-8415400-B2 | Synthesizing an amphiphilic block polymer micelle having ionically-charged polymeric segments and nonionically-charged polymeric segments; neutralizing under conditions that allow for self-assembly of polymer micelles; crosslinking; removing the moieties of opposite charge; drug delivery; stability | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100016392-A1 | Pesticidal Aggregates | INNOVAFORM TECHNOLOGIES, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2091323-A2 | PESTICIDAL AGGREGATES | Innovaform Technologies, LLC (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2003082348-A1 | NANOGEL NETWORKS INCLUDING POLYION POLYMER FRAGMENTS AND BIOLOGICAL AGENT COMPOSITIONS THEREOF | SUPRATEK PHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
| US-20020136769-A1 | Cross-linked polyionic polymer fragment and at least one nonionic water-soluble polymer fragment | BOARD OF REGENTS OF THE UNIVERSITYH OF NEBRASKA | 2002-09-26 | — | — | US | disclosed |
| US-6333051-B1 | FOR COMBINATORIAL DRUG DELIVERY, OR COMBINATORIAL FORMULATION | SUPRATEK PHARMA, INC. (CA) | 2001-12-25 | — | — | US | disclosed |
| EP-1109539-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2001-06-27 | — | — | EP | disclosed |
| EP-1005324-A4 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIV NEBRASKA (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1005324-A1 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000013677-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2000-03-16 | — | — | WO | disclosed |
| WO-1998056348-A1 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998056334-A1 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020136769-A1 | Cross-linked polyionic polymer fragment and at least one nonionic water-soluble polymer fragment | PUF60, CD44, PCLAF | BTN3A1 350/4885FDPS 3923/4885BLM 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.